Gilead Sets the Bar at 100% for Interferon-Free HCV Regimen
Gilead Sciences Inc. reported stunning interim results from its Phase II ELECTRON study of 12 weeks of therapy with investigational hepatitis C (HCV) combo sofosbuvir (GS-7977) and GS-5885 with ribavirin showing the best-possible results at four weeks after treatment, a 100 percent sustained virologic response (SVR4).
The trial enrolled 25 patients with genotype 1 chronic HCV, as is considered predictive of cure rates at 12 weeks after treatment (SVR12).
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST